Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2016 Nov 1;4(12):1016–1026. doi: 10.1158/2326-6066.CIR-16-0159

Figure 3.

Figure 3

IL2c rescues CD8+ T cells with established tolerance. (A) Diagram of experimental setup. (B) Transferred T-cell frequency in spleens on day 8. (C) Total number of transferred T cells in spleens at day 8 pooled from 3 separate experiments and error bars represent SEM. (D) Frequency of IFNγ or TNF positive cells from IL2c treated mice after restimulation with control (gray circles) or Gag peptide (black circles). (E) Relative frequency of Gag (efluorlow) and control (efluorhigh) peptide pulsed target cells. Inset numbers are the percent under each peak. (F) Tbx21−/− (CD90.1+) and WT (CD90.1+ CD90.2+) T cells were transferred into Alb:Gag recipients at a 1:1 ratio and the frequency of transferred cells in spleens assessed 8 days later. (G) Tbx21−/− and WT Gag-specific T cells were restimulated with control or Gag peptide and the frequency producing IFNγ or TNF was assessed. (H) Percent of transferred T cells producing IFNγ after restimulation with control peptide (gray circles) or Gag (black circles) pooled from 3 separate experiments.